Aylin Çoşkun

Dr. Aylin Çoşkun

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2016 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
FKFatih Mehmet Kelesoglu
Fatih Mehmet Kelesoglu
EAErhan Aygun
Erhan Aygun
NONazli Kubra Okumus
Nazli Kubra Okumus
AEAyşenur Ersoy
Ayşenur Ersoy
EKEdanur Karapınar
Edanur Karapınar
RORukiye Eker Omeroglu
Rukiye Eker Omeroglu

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
RÇRamazan Çakmak
Ramazan Çakmak
OCOzge Telci Caklili
Ozge Telci Caklili
AKAyşe Merve Ok Kurt
Ayşe Merve Ok Kurt
ÜMÜmmü Mutlu
Ümmü Mutlu
GSGöktuğ Sarıbeyliler
Göktuğ Sarıbeyliler
ISIlhan Satman
Ilhan Satman
Background and Aims: The age‐at‐onset is of great importance in the heterogeneity of Type 1 diabetes mellitus (T1DM). This study was designed to define clinical and laboratory differences between child–adolescent‐onset and adult‐onset T1DM at presentation and during follow‐up and determine the predicting factors for developing microvascular and macrovascular complications. Material and Methods: This retrospective observational study evaluated T1DM patients who were followed in the diabetes outpatient clinic between January 1, 2000, and December 31, 2019. Results: The study cohort included 490 individuals with T1DM (54.3% female, 58.8% adult‐onset, and median follow‐up: 5 years). In the adult‐onset group, baseline C‐peptide and GADA prevalence were higher, whereas presentation with ketoacidosis was 2.3‐fold lower compared to the child–adolescent‐onset group ( p < 0.001). During follow‐up, the adult‐onset group had a 2.4‐fold higher overweight/obesity ( p < 0.001) and 1.7‐fold higher dyslipidemia/hyperlipidemia ( p = 0.002) than the child–adolescent‐onset group. In multivariate analysis, fasting glucose ( p = 0.024) in adult‐onset, dyslipidemia/hyperlipidemia ( p = 0.037) in child–adolescent‐onset, and diabetes duration ( p = 0.008 and p = 0.007) and hypertension ( p = 0.001 and p = 0.01) in both groups were associated with increased risk of microvascular complications, whereas age‐at‐onset ( p = 0.024), dyslipidemia/hyperlipidemia ( p = 0.03), nephropathy ( p = 0.003), and neuropathy ( p = 0.001) in adult‐onset and age ( p = 0.002) and triglycerides ( p = 0.013) in child–adolescent‐onset groups were associated with increased risk of macrovascular complications. The cutoff C‐peptide levels at baseline predicted microvascular complications in the whole cohort and adult‐onset group were defined as 0.383 ng/mL ( p < 0.001) and 0.41 ng/mL ( p = 0.001), respectively. In the Kaplan–Meier analysis, C‐peptide (< 0.383 ng/mL) but not age‐at‐onset predicted future development of microvascular and macrovascular complications ( p = 0.003 and p = 0.032). Conclusion: Clinical presentation and prognosis differ in adult‐onset and child–adolescent‐onset T1DM. Low initial C‐peptide may predict the development of microvascular and macrovascular complications.

23 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AYArzu Yavuz
Arzu Yavuz
AÇAylin Çoşkun
Aylin Çoşkun
DUDilara Tekin Uzman
Dilara Tekin Uzman
EHEsra HATIPOGLU
Esra HATIPOGLU
Objective: Polycystic ovary syndrome (PCOS) and nonclassic congenital adrenal hyperplasia (NCAH) overlap clinically, but direct comparative data specifically addressing non-National Institutes of Health (non-NIH) Rotterdam phenotypes of polycystic ovary syndrome are limited. We compared women with polycystic ovary syndrome, of whom 66.7% were classified as having non-NIH Rotterdam phenotypes, with women with nonclassic congenital adrenal hyperplasia and healthy controls to characterize the extent of phenotypic overlap and evaluate the discriminatory performance of individual androgen measures. Methods: This single-center, prospective, exploratory cross-sectional study evaluated 58 women divided into three groups: PCOS (n = 24, Rotterdam criteria), NCAH due to 21-hydroxylase deficiency (n = 16, previously confirmed by adrenocorticotropic hormone (ACTH)-stimulated 17-hydroxyprogesterone (17-OHP)), and healthy controls (n = 18). Demographic, clinical, metabolic, and hormonal parameters were compared using analysis of variance (ANOVA), Kruskal–Wallis with Dunn’s post hoc test (Bonferroni-adjusted), and chi-square or Fisher’s exact tests. A sensitivity analysis was performed after excluding 12 participants receiving oral contraceptives (n = 8) or glucocorticoids (n = 4). Results: Within the PCOS group, 66.7% had non-NIH Rotterdam phenotypes. Hirsutism, defined as a modified Ferriman–Gallwey (mFG) score ≥ 8, was more frequent in both patient groups than in controls (p = 0.003) but did not differ between PCOS and NCAH. Total testosterone levels were 0.40 [0.20–0.60], 0.59 [0.45–0.94], and 0.20 [0.15–0.20] ng/mL in the PCOS, NCAH, and control groups, respectively, and androstenedione levels were 1.40 [1.20–2.20], 2.55 [1.64–4.07], and 0.87 [0.56–1.00] ng/mL, respectively; both were higher in the patient groups than in controls (both p < 0.001), without differing between PCOS and NCAH. Basal 17-OHP was the only parameter distinguishing NCAH from both PCOS and controls (p < 0.001). Dehydroepiandrosterone sulfate (DHEAS) levels were 356.5 [217–422], 292 [156–448], and 219 [146–240] µg/dL, respectively (p = 0.020), with a significant difference only between PCOS and controls. Anti-Müllerian hormone (AMH) levels were 3.27 [3.02–4.13], 3.13 [2.87–3.54], and 3.34 [2.93–5.37] ng/mL, respectively, with no between-group difference (p = 0.600). Other metabolic parameters, gonadotropins, estradiol, and prolactin showed no between-group differences. The principal hormonal findings remained unchanged after excluding women receiving oral contraceptives or glucocorticoids. Conclusions: In this PCOS cohort, in which 66.7% of women were classified as having non-NIH Rotterdam phenotypes, PCOS and NCAH showed substantial clinical, metabolic, and hormonal overlap, whereas basal early-follicular 17-OHP was the only parameter that consistently distinguished NCAH from both PCOS and healthy controls. These findings support the inclusion of basal 17-OHP in the evaluation of women presenting with hyperandrogenism.

1 November 2026 in The Prostate
Verified
Journal Article
Closed access
SKSerafettin Kaymak
Serafettin Kaymak
HCHalil Lutfi Canat
Halil Lutfi Canat
AÇAylin Çoşkun
Aylin Çoşkun
MCMuhammed Zeki Cicek
Muhammed Zeki Cicek
HBHamit Yucel Barut
Hamit Yucel Barut
EHEsra HATIPOGLU
Esra HATIPOGLU